These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9989716)

  • 1. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial.
    Cleare AJ; Heap E; Malhi GS; Wessely S; O'Keane V; Miell J
    Lancet; 1999 Feb; 353(9151):455-8. PubMed ID: 9989716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
    Cleare AJ; O'Keane V; Miell JP
    Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study.
    Blockmans D; Persoons P; Van Houdenhove B; Lejeune M; Bobbaers H
    Am J Med; 2003 Jun; 114(9):736-41. PubMed ID: 12829200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
    Blockmans D; Persoons P; Van Houdenhove B; Bobbaers H
    Am J Med; 2006 Feb; 119(2):167.e23-30. PubMed ID: 16443425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial.
    McKenzie R; O'Fallon A; Dale J; Demitrack M; Sharma G; Deloria M; Garcia-Borreguero D; Blackwelder W; Straus SE
    JAMA; 1998 Sep 23-30; 280(12):1061-6. PubMed ID: 9757853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial.
    Sulheim D; Fagermoen E; Winger A; Andersen AM; Godang K; Müller F; Rowe PC; Saul JP; Skovlund E; Øie MG; Wyller VB
    JAMA Pediatr; 2014 Apr; 168(4):351-60. PubMed ID: 24493300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma leptin in chronic fatigue syndrome and a placebo-controlled study of the effects of low-dose hydrocortisone on leptin secretion.
    Cleare AJ; O'Keane V; Miell J
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):113-9. PubMed ID: 11453960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.
    Forsyth LM; Preuss HG; MacDowell AL; Chiazze L; Birkmayer GD; Bellanti JA
    Ann Allergy Asthma Immunol; 1999 Feb; 82(2):185-91. PubMed ID: 10071523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo-controlled study.
    Young JL
    Psychiatry Res; 2013 May; 207(1-2):127-33. PubMed ID: 23062791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
    Younger J; Noor N; McCue R; Mackey S
    Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome.
    Olson LG; Ambrogetti A; Sutherland DC
    Psychosomatics; 2003; 44(1):38-43. PubMed ID: 12515836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome.
    McDermott C; Richards SC; Thomas PW; Montgomery J; Lewith G
    QJM; 2006 Jul; 99(7):461-8. PubMed ID: 16809351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome.
    Randall DC; Cafferty FH; Shneerson JM; Smith IE; Llewelyn MB; File SE
    J Psychopharmacol; 2005 Nov; 19(6):647-60. PubMed ID: 16272188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue.
    Olsson EM; von Schéele B; Panossian AG
    Planta Med; 2009 Feb; 75(2):105-12. PubMed ID: 19016404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome.
    Kaslow JE; Rucker L; Onishi R
    Arch Intern Med; 1989 Nov; 149(11):2501-3. PubMed ID: 2684076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome].
    Alegre J; Rosés JM; Javierre C; Ruiz-Baqués A; Segundo MJ; de Sevilla TF
    Rev Clin Esp; 2010 Jun; 210(6):284-8. PubMed ID: 20447621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
    Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
    Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.